The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline
QUESTION: 1. What are the most important diagnostic considerations in reporting progressive glioblastoma?.
TARGET POPULATION: These recommendations apply to adults with progressive glioblastoma.
RECOMMENDATIONS:.
LEVEL III: For patients who undergo biopsy or neurosurgical resection at the time of radiologic or clinical progression, it is recommended that the pathologist report the presence and extent of progressive neoplasm as well as the presence and extent of necrosis within the pathologic material examined. Furthermore, to ensure the proper interpretation of progressive glioblastoma, it is recommended that the pathologist take into account the patient's previous diagnosis and treatment, as well as the current clinical and neuroimaging features that have led to a second biopsy or resection.
QUESTION: 2. What techniques and ancillary studies are most useful in separating malignant progression from treatment effect?.
LEVEL III: In the setting of prior radiation and chemotherapy, it is recommended to adhere to strict histologic criteria for microvascular proliferation and necrosis in order to establish a diagnosis of a glioblastoma. Immunohistochemistry and genetic studies are selectively recommended for distinguishing neoplastic cells from atypical reactive cells in progressive glioblastoma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Journal of neuro-oncology - 118(2014), 3 vom: 14. Juli, Seite 461-78 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brat, Daniel J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 12.08.2014 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11060-013-1331-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM237375680 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM237375680 | ||
| 003 | DE-627 | ||
| 005 | 20231224111528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-013-1331-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0791.xml |
| 035 | |a (DE-627)NLM237375680 | ||
| 035 | |a (NLM)24733643 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brat, Daniel J |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of neuropathology in the management of progressive glioblastoma |b a systematic review and evidence-based clinical practice guideline |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2014 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a QUESTION: 1. What are the most important diagnostic considerations in reporting progressive glioblastoma? | ||
| 520 | |a TARGET POPULATION: These recommendations apply to adults with progressive glioblastoma | ||
| 520 | |a RECOMMENDATIONS: | ||
| 520 | |a LEVEL III: For patients who undergo biopsy or neurosurgical resection at the time of radiologic or clinical progression, it is recommended that the pathologist report the presence and extent of progressive neoplasm as well as the presence and extent of necrosis within the pathologic material examined. Furthermore, to ensure the proper interpretation of progressive glioblastoma, it is recommended that the pathologist take into account the patient's previous diagnosis and treatment, as well as the current clinical and neuroimaging features that have led to a second biopsy or resection | ||
| 520 | |a QUESTION: 2. What techniques and ancillary studies are most useful in separating malignant progression from treatment effect? | ||
| 520 | |a TARGET POPULATION: These recommendations apply to adults with progressive glioblastoma | ||
| 520 | |a RECOMMENDATIONS: | ||
| 520 | |a LEVEL III: In the setting of prior radiation and chemotherapy, it is recommended to adhere to strict histologic criteria for microvascular proliferation and necrosis in order to establish a diagnosis of a glioblastoma. Immunohistochemistry and genetic studies are selectively recommended for distinguishing neoplastic cells from atypical reactive cells in progressive glioblastoma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Systematic Review | |
| 700 | 1 | |a Ryken, Timothy Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Kalkanis, Steven N |e verfasserin |4 aut | |
| 700 | 1 | |a Olson, Jeffrey J |e verfasserin |4 aut | |
| 700 | 0 | |a AANS/CNS Joint Guidelines Committee |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d 1993 |g 118(2014), 3 vom: 14. Juli, Seite 461-78 |w (DE-627)NLM012591793 |x 1573-7373 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2014 |g number:3 |g day:14 |g month:07 |g pages:461-78 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11060-013-1331-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2014 |e 3 |b 14 |c 07 |h 461-78 | ||